Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-blind placebo-controlled pilot study of single-dose BAY 1067197 in chronic systolic heart failure patients receiving beta-blockers
NL-OMON38750Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of neladenoson bialanate in chronic heart failure (CHF) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Bayer. Primary endpoint: Occurrence of AV block greater than first degree. Started Dec 2014; status: active, not recruiting.
02
Drugs
neladenoson bialanate
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON38750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38750.